ClinicalTrials.gg
TerminatedNCT02282514SPSUpdated Jan 27, 2021Results posted

Stem Cell Transplantation for Stiff Person Syndrome (SPS)

A Phase 1/2 interventional study of Autologous Hematopoietic Stem Cells and Cyclophosphamide in Stiff-Person Syndrome, sponsored by Northwestern University. Terminated at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2021-01-27.

Sponsored by Northwestern University · Phase 1/2, Interventional, and Treatment

How we know

Why this study was terminated
Could not predict who would respond, relapse or go into remission

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Stiff-Person Syndrome with a site in United States — 4 open to participants now, 5 under way, 1 of them phase 3. Stiff-Person Syndrome · United States.

Enrollment
6th of 10
23 · median 24
Started
2014
the only one that year
Phase 1/2
Only one
of the 12
Registered
5th of 12
by date
Lead sponsor
1 of 12
Northwestern University

Among the 12 studies in Stiff-Person Syndrome with a site in United States, this one is the 6th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2014, is the only one in phase 1/2, and was the 5th registered.

Stiff-Person Syndrome

20 studies on the registry are indexed under Stiff-Person Syndrome; 8 are open to participants now.

Browse Stiff-Person Syndrome studies →

Open to participants now

4 of the 12 studies in Stiff-Person Syndrome with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 3 Stiff-Person Syndrome studies recruiting now, 2 set no upper age limit and none stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Stiff-Person Syndrome with a site in United States, or all of them as a file.
02

Study summary

Non-myeloablative regimens (as the investigators use herein) are designed to maximally suppress the immune system without destruction of the bone marrow stem cell compartment.

When using a non-myeloablative regimen recovery occurs without infusion of stem cells and the stem cells are autologous. While not necessary for recovery, stem cell infusion may shorten the interval of neutropenia and attendant complications. Thus in reality there is no transplant only an autologous supportive blood product.

Based on our encouraging results of non-myeloablative hematopoietic stem cell transplantation, for patients with multiple sclerosis and chronic inflammatory demyelinating polyneuropathy, the investigators will investigate the role of non-myeloablative hematopoietic stem cell transplantation for patients with SPS who require assistance to ambulate.

Read the detailed description

Pre-study Testing

  1. History and physical
  2. Electrocardiogram (EKG)
  3. Dobutamine stress echocardiogram
  4. High-resolution computed tomography of the chest (HRCT)
  5. Blood draw for laboratory tests- these tests will include a complete blood count, evaluating liver and kidney function, assessing immune system, tissue typing, and checking for certain germs that can cause infections, including a pregnancy test for females and prostate-specific antigen (PSA) for male as well as testing for HIV
  6. Pulmonary Function Test (PFT)
  7. Electromyography (EMG)
  8. Magnetic Resonance Imaging (MRI) of the Abdomen and Pelvis
  9. Magnetic Resonance Imaging (MRI) of the Spinal Cord
  10. Magnetic Resonance Imaging (MRI) of the Brain with Gadolinium (only if PERM of cerebellar ataxia)
  11. Colonoscopy
  12. Mammogram (if female)
  13. Timed ambulation
  14. Quality of Life Questionnaires [ Short Form (36) Health Survey (SF36) and Barthel Index]
  15. Chronic Pain Acceptance Questionnaire (CPAQ)
  16. Rankin Functional Scale
  17. Modified Ashworth Scale
  18. Purkinje Cell Cytoplasmic Antibody, Type 1 (PCA-1), Purkinje Cell Cytoplasmic Antibody, Type 2 (PCA-2) antibody (only if cerebellar ataxia)
  19. Spinocerebellar ataxia (SCA) 1, 2, 3, 4, 5, 6, 7, 8 genes (only if ataxia)

Study Treatment

Stem Cell Collection: Cyclophosphamide 2.0 gm/m2 will be given on day 0, G-CSF 5-10 mcg/kg/day subcutaneous (SQ) will start on day +5 and will continue until apheresis is discontinued. Apheresis will begin when the absolute neutrophil count (ANC) > 1.0 x 109/L and continue until >2.0 x 106 cluster of differentiation 34 (CD34)+ cells/kg patient weight are cryopreserved. A 10-15 liter apheresis will be performed unless stopped earlier for clinical judgment of toxicity (e.g., numbness, tetany). A maximum of four apheresis will be performed.

03

Conditions studied

  • Stiff-Person Syndrome

Keywords

  • Autoimmune Diseases
  • Autologous Hematopoietic Stem Cell Transplantation
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of Stiff-person Syndrome and

    • Age between 18 and 60 years old
    • Failure of medically tolerable doses (20-40 mg/day) of diazepam
    • Failure of either intravenous immunoglobulin (IVIg) and or plasmapheresis
    • Stiffness in the axial muscles, prominently in the abdominal and thoracolumbar paraspinal muscle leading to a fixed deformity (hyperlordosis)
    • Superimposed painful spasms precipitated by unexpected noises, emotional stress, tactile stimuli
    • Confirmation of the continuous motor unit activity in agonist and antagonist muscles by electromyography when off diazepam and anti-spasmatic medications
    • Absence of neurological or cognitive impairments that could explain the stiffness
    • Inability to run or walk, or abnormal gait
  2. Diagnosis of a SPS variant- Progressive Encephalomyelitis with Rigidity and Myoclonus (PERM) defined as:

    Acute onset of painful rigidity and muscle spasms in the limbs and trunk

    • Brainstem dysfunction (nystagmus, opsoclonus, ophthalmoparesis, deafness, dysarthria, dysphagia)
    • Profound autonomic disturbance.
    • Positive serology for GAD65 (or amphiphysin) autoantibodies, assessed by immunocytochemistry, western blot or radioimmunoassay (>1000 u/ml)
    • MRI may show increased signal intensity throughout the spinal cord and the brainstem
  3. Diagnosis of a SPS variant - anti-GAD positive cerebellar ataxia

    • Subacute or chronic onset of cerebellar symptoms-gait or limb ataxia, dysarthria, nystagmus
    • Positive serology for GAD65 (or amphiphysin) autoantibodies, assessed by immunocytochemistry, western blot or radioimmunoassay (>1000 u/ml)
    • Anti-GAD antibody in cerebrospinal fluid
    • Abnormal MRI imaging of brainstem or cerebellum other than cerebellar atrophy
    • Negative history of toxin or alcohol
    • Absence of Vitamin B12 or Vitamin E deficiency
    • Absence of positive , syphilis or whipple disease
    • Absence of consanguinity, positive family history for ataxia or positive genetic screen for spinocerebellar ataxia (SCA) 1, SCA 2, SCA 3, SCA 6, SCA 7 or SCA 8 mutation

Exclusion criteria

Exclusion Criteria:

  • Current or prior history of a or paraneoplastic syndrome
  • Inability to sign and understand consent and be compliant with treatment
  • Positive pregnancy test
  • Inability to or comprehend irreversible sterility as a possible side effect
  • Amphiphysin antibody positive
  • (LVEF) \< 45% or ischemic coronary artery disease on dobutamine stress echocardiogram
  • Diffusing capacity of the lungs for carbon monoxide (DLCO) \< 60% predicted
  • Serum creatinine > 2.0 mg/dl
  • >2.0 mg/dl
  • count \< 100,000 / ul, white blood cell count (WBC) \< 1,500 cells/mm3
  • History of toxin or alcohol abuse
  • History of Vitamin B12 or Vitamin E deficiency
  • Positive , syphilis, or whipple disease
  • Consanguinity, positive family history for ataxia or positive genetic screen for SCA1, SCA2, SCA3, SCA6, SCA 7 or SCA8 mutation (if ataxia present)
  • Absence of at least one SPS associated antibody such as anti-GAD, or gamma-aminobutyric acid (GABA)-A receptor associated protein, or synaptophysin, or gephyrin, or GABA-transaminase
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Hematopoietic Stem Cell Transplantation

    The conditioning regimen will be 200 mg/kg of intravenous cyclophosphamide given in 4 equal fractions on days -5 through -2 with intravenous mesna. Rabbit antithymocyte globulin (rATG) (Thymoglobulin®) will be dosed at 0.5 mg/kg on day-5, 1.0 mg/kg on days -4 and -3, and then 1.5 mg/kg on days -2 and -1. Methylprednisolone 1000 mg will be infused intravenously before each dose of rATG. Autologous hematopoietic stem cells will be infused intravenously on day 0. A granulocyte-colony stimulating factor (G-CSF) 5-10 mcg/kg will be started on day + 5 and continued until neutrophil engraftment. Intravenous Rituxan (500mg) will be administered on days -6 and +1.

    Biological: Autologous Hematopoietic Stem Cells · Drug: Cyclophosphamide · Drug: Mesna · Drug: rATG · Drug: Methylprednisolone · Drug: G-CSF · Drug: Rituxan

Interventions

  • BiologicalAutologous Hematopoietic Stem Cells

    The stem cells will be collected from patient's blood during mobilization. Then the patient will be given high dose chemotherapy in accordance with approved recommendations for use in conditioning regimens for stem cell transplant in autoimmune diseases. Autologous Hematopoietic Stem Cell Transplantation is to re-infuse immature cells that can re-establish blood production and patient's immune system.

  • An alkylating agent which causes prevention of cell division by forming adducts with DNA

    Also known as: Cytoxan, Neosar, Endoxan

  • DrugMesna

    Medication used to decrease the risk of hemorrhagic cystitis prophylaxis

    Also known as: Mesnex

  • DrugThymoglobulinStudies of ThymoglobulinThymoglobulin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A predominantly lymphocyte-specific immunosuppressive agent which contains antibodies specific to the antigens commonly found on the surface of T cells

    Also known as: Thymoglobulin

  • Steroid

    Also known as: Solu-Medrol

  • DrugGranulocyte Colony-Stimulating FactorStudies of Granulocyte Colony-Stimulating FactorGranulocyte Colony-Stimulating Factor pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Granulocyte-colony stimulating factor; a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream

    Also known as: Neupogen, Filgrastim, Granix, Zarxio

  • DrugRituximabStudies of RituximabRituximab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A chimeric monoclonal antibody used in the treatment of B cell non-Hodgkin's lymphoma, B cell leukemia, and some autoimmune disorders

    Also known as: Rituximab

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Number of Participants who Did Not Experience Treatment-Related Mortality

    Time frame: Mean 3.6 years

Secondary outcomes

  1. Reduction of Muscle Relaxation Anti-spasmatic Medications

    Decrease (50%) and complete discontinuation of muscle relaxation anti-spasmatic medications

    Time frame: Mean 3.6 years

  2. Short-form 36 Quality of Life Questionnaire (SF-36 QOL)

    Improvement is defined as a statistically significant change in SF-36 QOL score. The scale is 0-100. The lower the score the worse quality of life.

    Time frame: mean 3.6 years

07

Results

Posted Jan 6, 2021

Participant flow

Participant flow — Overall Study
MilestoneHematopoietic Stem Cell Transplantation
Started23
Completed23
Not completed0

Outcome measures

PrimaryOverall Survival

Number of Participants who Did Not Experience Treatment-Related Mortality

Time frame:
Mean 3.6 years
Reported as:
Number · participants
Overall Survival
participantsHematopoietic Stem Cell Transplantation
Overall Survival23
SecondaryReduction of Muscle Relaxation Anti-spasmatic Medications

Decrease (50%) and complete discontinuation of muscle relaxation anti-spasmatic medications

Time frame:
Mean 3.6 years
Reported as:
Count of participants · Participants
Reduction of Muscle Relaxation Anti-spasmatic Medications
ParticipantsHematopoietic Stem Cell Transplantation
Reduction of Muscle Relaxation Anti-spasmatic Medications14
SecondaryShort-form 36 Quality of Life Questionnaire (SF-36 QOL)

Improvement is defined as a statistically significant change in SF-36 QOL score. The scale is 0-100. The lower the score the worse quality of life.

Time frame:
mean 3.6 years
Reported as:
Geometric mean · units on a scale
Short-form 36 Quality of Life Questionnaire (SF-36 QOL)
units on a scaleHematopoietic Stem Cell Transplantation
Pre Treatment37.75 ± 12.81
Post Treatment58.35 ± 22.81

Adverse events

Collected over Up to 4.5 years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Hematopoietic Stem Cell Transplantation1/23 (4.3%)1/23 (4.3%)5/23 (21.7%)
Most frequent serious events
Most frequent serious events
EventHematopoietic Stem Cell Transplantation
Non Treatment Related DeathGeneral disorders1/23
Most frequent other events
Most frequent other events
EventHematopoietic Stem Cell Transplantation
HyperglycemiaEndocrine disorders5/23

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Hematopoietic Stem Cell Transplantation
<=18 years0
Between 18 and 65 years23
>=65 years0
Age, Continuous
Age, Continuous(Years)Hematopoietic Stem Cell Transplantation
Mean48.3 (27 to 60)
Sex: Female, Male
Sex: Female, Male(Participants)Hematopoietic Stem Cell Transplantation
Female21
Male2
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Hematopoietic Stem Cell Transplantation
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American3
White17
More than one race0
Unknown or Not Reported1
Region of Enrollment
Region of Enrollment(participants)Hematopoietic Stem Cell Transplantation
United States23
08

Study locations

1 site
  • Northwestern University
    Chicago, Illinois 60611, United States
09

References and documents

Publications

  • Burt RK, Balabanov R, Han X, Quigley K, Arnautovic I, Helenowski I, Rose J, Siddique T. Autologous Hematopoietic Stem Cell Transplantation for Stiff-Person Spectrum Disorder: A Clinical Trial. Neurology. 2021 Feb 9;96(6):e817-e830. doi: 10.1212/WNL.0000000000011338. Epub 2020 Dec 14. PubMed 33318163 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2014, a primary completion of Aug 2019 and a completion of Aug 2019. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2021, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2014
First posted
Nov 4, 2014
Start
Oct 2014
Primary completionActual
Aug 19, 2019
CompletionActual
Aug 30, 2019
Results first posted
Jan 6, 2021
Last update
Jan 27, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02282514
Responsible party
Richard Burt, MD (Professor, Division Chief, Northwestern University) — Principal investigator
First posted
Nov 4, 2014
Start date
Oct 2014
Primary completion
Aug 19, 2019
Completion
Aug 30, 2019
Results posted
Jan 6, 2021
Last update
Jan 27, 2021

Study contacts

Richard Burt, MD
principal investigator · Northwestern University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cyclophosphamide · Mesna · Thymoglobulin · Methylprednisolone · Granulocyte Colony-Stimulating Factor · Rituximab

Start the discussion